Could CAR t cells tame severe vasculitis without lifelong drugs?
NCT ID NCT07388277
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-phase trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful B cells. It is for 12 adults with severe ANCA-associated vasculitis that has not responded to standard therapies. The main goals are to check safety and see if it can lead to remission without needing ongoing immune-suppressing medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-97540 (CAR T cells targeting CD19) plus lymphodepletion chemotherapy
What this could lead to
If it works, this could point toward a treatment that puts severe vasculitis into long-term remission without needing lifelong immune-suppressing drugs.
What could go wrong
This is a very early, small trial (12 people) focused on safety. CAR T cells can cause serious side effects like cytokine release syndrome, and it may not work or may not lead to lasting remission.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.